Advertisement

Canadian Journal of Public Health

, Volume 105, Issue 4, pp e287–e295 | Cite as

Is herpes zoster vaccination likely to be cost-effective in Canada?

  • Alexander D. PedenEmail author
  • Stephenson B. Strobel
  • Evelyn L. Forget
Systematic Review

Abstract

OBJECTIVES: To synthesize the current literature detailing the cost-effectiveness of the herpes zoster (HZ) vaccine, and to provide Canadian policymakers with cost-effectiveness measurements in a Canadian context.

METHODS: This article builds on an existing systematic review of the HZ vaccine that offers a quality assessment of 11 recent articles. We first replicated this study, and then two assessors reviewed the articles and extracted information on vaccine effectiveness, cost of HZ, other modelling assumptions and QALY estimates. Then we transformed the results into a format useful for Canadian policy decisions. Results expressed in different currencies from different years were converted into 2012 Canadian dollars using Bank of Canada exchange rates and a Consumer Price Index deflator. Modelling assumptions that varied between studies were synthesized. We tabled the results for comparability.

SYNTHESIS: The Szucs systematic review presented a thorough methodological assessment of the relevant literature. However, the various studies presented results in a variety of currencies, and based their analyses on disparate methodological assumptions. Most of the current literature uses Markov chain models to estimate HZ prevalence. Cost assumptions, discount rate assumptions, assumptions about vaccine efficacy and waning and epidemiological assumptions drove variation in the outcomes. This article transforms the results into a table easily understood by policy-makers.

CONCLUSION: The majority of the current literature shows that HZ vaccination is cost-effective at the price of $100,000 per QALY. Few studies showed that vaccination cost-effectiveness was higher than this threshold, and only under conservative assumptions. Cost-effectiveness was sensitive to vaccine price and discount rate.

Key Words

Review cost-benefit analysis public policy 

Résumé

OBJECTIFS: Faire une synthèse de la littérature actuelle sur le rapport coût-efficacité du vaccin contre le virus de l’herpès zoster (zona) et fournir aux responsables des politiques du Canada des indicateurs coûtefficacité dans un contexte canadien.

MÉTHODE : Cet article fait fond sur une revue systématique existante qui évalue la qualité de 11 articles récents portant sur le vaccin contre le zona. Nous avons d’abord reproduit l’étude, après quoi deux évaluateurs ont examiné les articles et en ont extrait l’information sur l’efficacité du vaccin, le coût du zona, les autres postulats de modélisation et les estimations des années de vie pondérées par la qualité (AVPQ). Ensuite, nous avons transposé les résultats sous une forme utile aux décisions stratégiques canadiennes. Les résultats, exprimés en différentes devises pour différentes années, ont été convertis en dollars canadiens de 2012 à l’aide des taux de change de la Banque du Canada et d’un déflateur: l’indice des prix à la consommation. Les postulats de modélisation variables d’une étude à l’autre ont été synthétisés. Nous avons mis les résultats en tableaux pour pouvoir les comparer.

SYNTHÈSE : La revue systématique de Szucs présentait une évaluation méthodologique exhaustive de la littérature pertinente. Cependant, les résultats des diverses études étaient présentés dans toutes sortes de devises, et les analyses étaient fondées sur des postulats méthodologiques disparates. La plupart des articles récents font appel aux modèles en chaînes de Markov pour estimer la prévalence du zona. Les postulats relatifs aux coûts, aux taux d’actualisation, à l’efficacité potentielle du vaccin, à la baisse de l’immunité conférée par le vaccin, ainsi que les postulats épidémiologiques, ont fait varier les résultats. Notre article transpose ces résultats dans un tableau facile à comprendre pour les responsables des politiques.

CONCLUSION : Selon la majorité des articles récents, la vaccination contre le zona est rentable au prix de 100 000 $ par AVPQ. Peu d’études indiquent un rapport coût-efficacité de la vaccination supérieur à ce seuil, et seulement sur la base de postulats prudents. Le rapport coût-efficacité était sensible au prix et au taux d’actualisation du vaccin.

Mots Clés

revue de la littérature analyse coût-bénéfice politique publique 

References

  1. 1.
    Drolet M, Brisson M, Levin MF, Schmader KE, Oxman MN, Johnson RW, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010;26(8):656–66.PubMedGoogle Scholar
  2. 2.
    Bennett GJ, Watson CPN. Herpes zoster and postherpetic neuralgia: Past, present and future. Pain Res Manage 2009;14(4):275–82.CrossRefGoogle Scholar
  3. 3.
    Sanford M, Keating, GM. Zoster vaccine: A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010:27(2):159–76.CrossRefGoogle Scholar
  4. 4.
    Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271–84.CrossRefGoogle Scholar
  5. 5.
    Szucs T, Pfeil A. A systematic review of the cost effectiveness of herpes zoster vaccination. PharmacoEconomics 2013;31:125–36.CrossRefGoogle Scholar
  6. 6.
    Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55(10):1320–28.CrossRefGoogle Scholar
  7. 7.
    Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010;13(3):537–51.CrossRefGoogle Scholar
  8. 8.
    Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Costeffectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012;30:675–84.CrossRefGoogle Scholar
  9. 9.
    Edmunds WJ, Brisson M, Rose, JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076–90.CrossRefGoogle Scholar
  10. 10.
    Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317–25.CrossRefGoogle Scholar
  11. 11.
    Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the, UK. Cost Effectiveness and Resource Allocation 2010;8(7):1–14.Google Scholar
  12. 12.
    Najafzadeh M, Marra CA, Galanis E, Patrick, DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009;27(12):991–1004.CrossRefGoogle Scholar
  13. 13.
    Pellissier JM, Brisson M, Levin, MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326–37.CrossRefGoogle Scholar
  14. 14.
    Rothberg MB, Virapongse A, Smith, KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. CID 2007;44:1280–88.CrossRefGoogle Scholar
  15. 15.
    Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel J-P, Fendl A, Bresse X. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Human Vaccines 2011;7(7):749–56.CrossRefGoogle Scholar
  16. 16.
    Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds, JH. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454–67.CrossRefGoogle Scholar
  17. 17.
    Van Lier A, van Hoek AJ, Opstelten W, Boot JH, de Melker, HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Services Research 2010;10(237):1–10.Google Scholar
  18. 18.
    Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health 2008;99(5):383–86.PubMedGoogle Scholar
  19. 19.
    Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137(1):38–47.CrossRefGoogle Scholar
  20. 20.
    Oster G, Harding G, Dukes E, Edelsberg J, Clearly, PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain 2005;6:356–63.CrossRefGoogle Scholar
  21. 21.
    Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O’Brien B. Valuing outcomes in health care: A comparison of willingness to pay and qualityadjusted life years. Clin Epidemiol 1998;51:667–76.CrossRefGoogle Scholar
  22. 22.
    Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain 2004;5(6):344–56.CrossRefGoogle Scholar
  23. 23.
    Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2006.Google Scholar
  24. 24.
    Grosse, SD. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8(2):165–78.CrossRefGoogle Scholar
  25. 25.
    Laupacis A, Feeny D, Detsky AS, Tugwell, PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–81. Available at: http://www.ncbi.nlm.nih.gov (Accessed August 2, 2013).PubMedPubMedCentralGoogle Scholar
  26. 26.
    World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Cost-effectiveness thresholds. Available at: http://www.who.int (Accessed August 2, 2013).Google Scholar
  27. 27.
    Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Breuer J. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003;70(Suppl 1):S24–30.CrossRefGoogle Scholar
  28. 28.
    Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas, AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748–53.CrossRefGoogle Scholar
  29. 29.
    Grant DM, Mauskopf JA, Bell L, Austin R. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: A cost-consequence model. Pharmacotherapy 1997;17:333–41.PubMedGoogle Scholar
  30. 30.
    Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: A prospective population based study. Vaccine 2006;24(9):1308–14.CrossRefGoogle Scholar
  31. 31.
    van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, Verheij, TJ. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: A randomised controlled trial. Lancet 2006;367:219–24.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2014

Authors and Affiliations

  • Alexander D. Peden
    • 1
    Email author
  • Stephenson B. Strobel
    • 1
  • Evelyn L. Forget
    • 1
  1. 1.Dept. of Community Health Sciences, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations